Community Practitioners and Health Visitors Association

Back to home pageGeneral information about CPHVAMembership information Contact CPHVA staffSearch CPHVA site for general informationHelp on navigating the siteLinks to other useful sitesEnter members' area

Health visiting information
School nursing information District nursing information Practice nursing information Countries-Scotland, Wales and Northern IrelandPublic health information Clinical effectiveness information Courses, grants and reportsCPHVA responses to government and other reportsCPHVA and non-CPHVA eventsPress releases and media relationsCPHVA campaignsSpecial Interest GroupsFrequently asked questionsIndex to site


NICE reverses ban on pimecrolimus


The National Institute for Clinical Excellence (NICE) is to overturn a recommendation to ban pimecrolimus (Elidel) as a second line treatment for moderate atopic eczema on the face and neck in children aged 2 to 16 years.

The preliminary recommendation was made in a consultation report in April but experts and patient groups told NICE that pimecrolimus was a useful alternative to topical steroid treatment for atopic eczema.

NICE are now recommending in a final appraisal determination report that pimecrolimus can be used within its licensed indications as an option for the second-line treatment of moderate atopic eczema on the face and neck in children aged 2 to 16 years. It says it should be used for eczema that has not been controlled by topical corticosteroids and where there is a serious risk of adverse effects from further topical corticosteroid use, particularly irreversible skin atrophy.

The final recommendation will be published as an official ruling in a few weeks. Further information from